Market Newsdesk

PALM BEACH, FL, April 05, 2021 (GLOBE NEWSWIRE) — FLEXI NUTRITION introduced its dietary supplements to buyers from large and small retail chains, such as CVS and Walgreens, at last month’s ECRM program.

The private one-on-one virtual meetings between retailers and the manufacturer of IRISH WHEY, FURY Ultimate Pre-Workout, and FURY Extreme Pre-Workout Shots took place last month at ECRM’s “Healthy Living, Vitamins & Nutrition Program.”

“Our representative promoted FLEXI NUTRITION to large and small retail chains in the United States,” said Shane Kennedy, CEO and founder of FLEXI NUTRITION. “We are proud of our high-quality dietary supplements, which are considered the best sports nutrition products in Ireland.”

Kennedy said FLEXI NUTRITION developed its dietary supplements to boost athletic performance, strength, and overall personal health and fitness.

“Our research and development team works with sports nutritionists and food scientists to develop high-quality products for today’s athletes and health-conscious consumers,” Kennedy added.

The three FLEXI NUTRITION products that debuted at ECRM are:

• IRISH WHEY is manufactured from sustainably farmed, Irish Grass-Fed, and Free-Range Whey Protein, which is also Gluten and GMO-Free. IRISH WHEY provides the perfect balance of essential and non-essential Amino Acids, including a high concentration of Branch Chain Amino Acids (BCAAs). It is the perfect nutritional component to complement your muscle growth, fat loss, or fitness program. Great taste and mixability.
• FURY Extreme Pre-Workout Shot is a Sugar-Free grab-and-go product that targets improved mental and cognitive function for high performance during intense workouts. Ingredients include high caffeine content, L-Tyrosine, Beta-Alanine, B-Vitamins, Citrulline Malate, and Arginine. No mixing is required. Three great flavors.
• FURY Ultimate Pre-Workout Energizer is the most powerful, most effective, and most advanced pre-workout catalyst on the market. It delivers prolonged explosive energy and intense focus without the crash associated with other pre-trainers. Ingredients include high caffeine content, L-Tyrosine, Beta-Alanine, B-Vitamins, Citrulline Malate, and Arginine. Great taste and mixability.

One of FLEXI NUTRITION’S most highly regarded products is its IRISH WHEY Protein, which comes from sustainably farmed, free-range, grass-fed dairy. IRISH WHEY contains an optimum blend of Instantised, De-Lactosed Pure Whey Protein Isolate, Whey Protein Concentrate, and Hydrolysed Whey.

“IRISH WHEY beats any other brand on the market,” he said.

Kennedy said serious bodybuilders and athletes will benefit from FLEXI NUTRITION’s rapid absorption formulas, which include high levels of BCAAs, and the premium quality protein contained in its IRISH WHEY.

All the products are manufactured in an Informed Sports Certified Facility, which guarantees that the supplements have been tested for banned substances by the world-class sports and anti-doping laboratory, LGC.

“We take developing world-class sports nutrition for serious athletes seriously, which is why we test every batch for banned substances,” Kennedy said. “Athletes don’t have to worry about testing positive for a banned substance with FLEXI NUTRITION supplements.”

FLEXI NUTRITION also uses sustainable manufacturing techniques for its Irish Whey Protein, while Fury and Fury Shot are vegan-friendly products. The company uses bio-degradable packaging for its Fury Shot.

FLEXI NUTRITION dietary supplements are highly regarded in Ireland for their premium quality. During the past several years, the company received the “Best in Sports Nutrition” honor from the Irish Business Summit and was a 2019 finalist in the “Best in Sports Nutrition” from the Irish Fitness Industry Awards.

“We are honored that other organizations acknowledge our high-quality products,” Kennedy said, adding that FLEXI NUTRITION’s supplements are safe and great tasting.

For more information, please visit FLEXI NUTRITION online.

Attachments

• Flex Nutrition – whey – Flyer A5 Rev
• FURY – White Background

LOS ANGELES, April 05, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 7, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired XL Fleet Corp. (“XL Fleet” or the “Company”) (NYSE: XL) securities between October 2, 2020 and March 2, 2021, inclusive (the “Class Period”).

If you suffered a loss on your XL Fleet investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/xl-fleet-corp/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On March 3, 2021, Muddy Waters Research published a report entitled “XL Fleet Corp. (NYSE: XL): More SPAC Trash,” alleging, among other things, that salespeople “were pressured to inflate their sales pipelines materially in order to mislead XL’s board and investors” and that “customer reorder rates are in reality quite low” due to “poor performance and regulatory issues.” Citing interviews with former employees, the report alleged that “at least 18 of 33 customers XL featured were inactive.” Muddy Waters also claimed that XL has “weak technology” and that “XL’s announcement of future class 7-8 upfits seems highly promotional” because the task is “too technologically complex for XL engineers to deliver on the promised timeline.”

On this news, the Company’s stock price fell $2.09, or 13%, to close at $13.86 per share on March 3, 2021, on unusually heavy trading volume. The share price continued to decline by $2.69, or 19.4%, over two consecutive trading sessions to close at $11.17 per share on March 5, 2021, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that XL Fleet’s salespeople were pressured to inflate their sales pipelines to boost the Company’s reported sales and backlog; (2) that at least 18 of the 33 customers that XL featured were inactive and had not placed an order since 2019; (3) that XL’s technology had been materially overstated and offered only 5% to 10% of fleet savings; (4) that XL lacks the supply chain and engineers to roll out new products on the announced timelines; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired XL Fleet securities during the Class Period, you may move the Court no later than May 7, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

BENSALEM, Pa., April 05, 2021 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected].

CytoDyn, Inc. (OTC: CYDY) 
Class Period: March 27, 2020 – March 9, 2021
Lead Plaintiff Deadline: May 17, 2021 

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements touting Leronlimab as a potential treatment for COVID-19 to pump up the CytoDyn’s stock price while executives aggressively sold their shares. The complaint also alleges that CytoDyn engaged in a wrongful scheme whereby Iliad and other Fife entities operated as an unregistered securities dealer for CytoDyn.

Root, Inc. (NASDAQ: ROOT)
Class Period: October 28, 2020 – March 8, 2021
Lead Plaintiff Deadline: May 18, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Offering Documents and Defendants failed to disclose to investors that: (1) Root would foreseeably fail to generate positive cash flow for at least several years following the IPO; (2) accordingly, the Company would foreseeably require significant cash infusions to meet its cash flow needs; (3) notwithstanding the Defendants’ touting of Root’s purportedly unique, data-driven advantages, several of the Company’s established industry peers in fact possessed significant competitive advantages over Root with respect to, inter alia, telematics data and data engagement; and (4) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

Vroom, Inc. (NASDAQ: VRM)
Class Period: June 9, 2020 – March 3, 2021
Lead Plaintiff Deadline: May 21, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) that, as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) that, as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD)
Class Period: August 4, 2020 – January 25, 2021
Lead Plaintiff Deadline: May 25, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) starting in January 2020, KORU ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company’s net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

LOS ANGELES, April 05, 2021 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Leidos Holdings, Inc. (“Leidos” or the “Company”) (NYSE: LDOS) securities between May 4, 2020 and February 23, 2021, inclusive (the “Class Period”). Leidos investors have until May 3, 2021 to file a lead plaintiff motion.

If you suffered a loss on your Leidos investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/leidos-holdings-inc. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 16, 2021, Spruce Point Capital Management LLC (“Spruce Point”) published a research report, alleging, among other things that “Leidos is potentially covering up at least $100m of fictitious sales, mischaracterizing $355 – $367m of international revenue.” The report also alleged that the Company was “concealing numerous product defects from investors, notably faulty explosive detection systems at airports and borders.”

On this news, the Company’s share price fell $2.58, or 2.4%, to close at $105.22 per share on February 16, 2021, on unusually heavy trading volume.

On February 23, 2021, Leidos announced its fourth quarter and full year 2020 financial results in a press release. Therein, the Company reported $89 million revenue related to the SD&A businesses for the fourth quarter, meaning that after two full quarters, the acquisition generated only $163 million in sales (or $326 million annualized), falling well short of projected $500 million sales. The Company expected cash flow of $850 million, well below analyst estimates of $1.083 billion.

On this news, the Company’s stock price fell $10.29, or 9.91%, to close at $93.51 per share on February 23, 2021.

On February 24, 2021, Spruce Point highlighted that Leidos had “materially expanded” the risk disclosures in its annual report for the year ended December 31, 2020. Spruce Point tweeted: “We believe it is validating all the major points of our report.”

On this news, the Company’s stock price fell $3.13, or 3.3%, to close at $90.38 per share on February 24, 2021, on unusually heavy trading volume.

Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the purported benefits of the Company’s acquisition of L3Harris’ Security Detection & Automation businesses were significantly overstated; (2) that Leidos’ products suffered from numerous product defects, including faulty explosive detection systems at airports, ports, and borders; (3) that, as a result of the foregoing, the Company’s financial results were significantly overstated; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Leidos securities during the Class Period, you may move the Court no later than May 3, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

Minneapolis, MN, April 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Carrot Health, a leading provider of healthcare solutions powered by consumer and claims data, announced today CEO Kurt Waltenbaugh was named one of 2021’s Health Care Heroes by the Minneapolis/St. Paul Business Journal. Waltenbaugh, who was recognized in the Health Entrepreneur category, was honored for his substantial achievements at the helm of Carrot Health and the impact he and the company have had on the Minneapolis/St. Paul Community.

Recognizing that 2020 was an unprecedented year, the Business Journal launched the Health Care Heroes awards to honor the healthcare workers who have gone above and beyond in their efforts to fight the global COVID-19 pandemic while continuing to provide care for non-COVID patients. The program recognizes Twin Cities’ individuals who have put innovation, care, dedication, and compassion to work to improve the human condition. Honorees were announced on April 5* by the Business Journal and will be recognized during a virtual event on June 10 and in a June 11 special print edition.

Waltenbaugh stood out for his dedication to shining the bright light of data onto healthcare and societal disparities—the very disparities that collided in 2020 when the world was gripped simultaneously by the pandemic and racial unrest that exploded in the wake of George Floyd’s death—to enable a future without barriers to better health for everyone. He co-founded Carrot Health in 2014 as the vehicle for applying the power of data to eliminating the systemic barriers that prevent people from leading their healthiest lives.

Over the past year, Waltenbaugh’s passion for addressing the social determinants of health (SDoH) that create health disparities and impact public health and public safety resulted in development of Carrot Health’s COVID-19 Critical Infection Risk Dashboard, which predicts the populations and communities that are most susceptible to the negative impacts from a coronavirus outbreak. It also led to the launch of the Carrot Social Risk Grouper® (SRG), which was developed to help understand, identify, measure, and quantify the social barriers and circumstances in which people live. It identifies who is most at risk in a population to help determine which interventions may help lead to better health outcomes.

The impact of Waltenbaugh’s work through Carrot Health can be seen locally in St. Paul’s Frogtown community, where the SRG was used to understand the health risks associated with the 35,000 adult residents. By determining the most prevalent causes for high health risk—financial insecurity among the Hmong population and housing instability among the Black population—the SRG paves the way for designing a solution that enables all of Frogtown’s residents to lead their healthiest lives.

Waltenbaugh is also focused on applying data to address the region’s public health and public safety issues created by the disparities that were laid bare by the pandemic and Floyd’s death and subsequent riots. This includes working with neighbors and elected officials to determine the community’s best response to effectively alleviate the sort of systemic conditions that were clearly exacerbated by the dual crises.

“Being recognized as one of the Twin Cities’ Health Care Heroes is an honor,” said Waltenbaugh. “My heroes are my colleagues who joined me in building Carrot Health, and our customers who are committed to health equity and removing barriers to ensure that everyone has the opportunity to live their best life.”

He continued: “I am honored to be recognized with so many others who are similarly dedicated to improving community and health.”

Follow Carrot Health via Twitter and LinkedIn and listen to our podcast, Carrot Shtick.

* Subscription may be required to access the full article.

About Carrot Health

Carrot Health believes in enabling a future with no barriers to better health, for everyone. We believe that shining the bright light of data onto our disparities will help us, all working together, to improve health. We provide consumer insights for each and every individual person in the United States to engage patients and members, close gaps in care, and optimize performance for healthcare payers and provider systems. The Carrot MarketView® software platform incorporates social, behavioral, environmental, and economic barriers to health data to deliver a 360-degree view of the consumer, providing actionable insights to inform Growth, Health, and Quality.

Liz Goar
813-333-2844
[email protected]

PALM BEACH, FL, April 05, 2021 (GLOBE NEWSWIRE) — OnMi “Patch It On” dietary supplements went on 50 dates last week with buyers from large and small retail chains in the United States. 

OnMi took part in ECRM’s “Healthy Living, Vitamins & Nutrition Program,” an industry leader that brings together retail buyers and manufacturers of new products in one-on-one meetings.

“We are quite excited that buyers from major retailers in the United States got to learn about OnMi vitamin and plant-based supplements,” said Ryan McFarlane, COO of OnMi, a Miami-based health and wellness company. “We developed a transdermal patch that makes it easy for anyone to take their daily essential vitamins.

McFarlane emphasized that OnMi delivers vitamins and botanicals without sugar and potentially harmful filler ingredients.

“OnMi’s ‘Patch it On’ supplements also avoid the gastro-intestinal tract where gastric acids can reduce the effectiveness of nutritional supplements that are swallowed,” he added.

OnMi supplements stand apart from other nutritional supplements because of their delivery method and ingredients, or more importantly, what is not in OnMi supplements.

“Our delivery method is perfect for many people who have trouble swallowing pills,” McFarlane said. “With OnMi, all you have to do is put the patch on your arm.

“Plus, our vitamins don’t have ingredients used for manufacturing purposes, such as lubricants added for the machines that make the pills or tablets,” he added.

McFarlane said consumers don’t realize many dietary supplements contain 10 percent vitamins and 90 percent filler ingredients, such as silicon dioxide and microcrystalline cellulose, which are potentially harmful.

“Our patch supplements deliver 100 percent vitamins and botanicals without the filler ingredients,” he said.

OnMi developed supplements that fit everyone’s needs:

• Vitamin: This patch is an easy way to get your daily essential vitamins, with no fillers or sugar.
• Crave-Less: This patch helps you say no to cravings with focus and energy.
• Relax: This patch promotes relaxation and helps you manage everyday stress.
• Energy: This power-up patch provides sustainable energy with a boost of antioxidants.
• Healthy Weight: This patch supports healthy weight maintenance along with a balanced diet and exercise.
• Hangover: Boost your body’s ability to bounce back by replenishing essential vitamins plus guarana.
• Sleep: This patch supports healthy sleep cycles and promotes quality rest.

OnMi products, which only contain plant-based ingredients and vitamins, are also Non-GMO, Hypoallergenic, Paraben Free, Dye Free, Gluten-Free, Sugar-Free, and Latex Free.

“This is an exciting year for OnMi,” McFarlane said. “We are looking to follow up with the retailers our representative met at ECRM. We are optimistic that the retailers will see that many consumers want an alternative to pill-popping their vitamins.”

For more information, visit onmipatch.com.

Attachments

• OnMi Retail Launch Collection
• OnMi Patch Example